

2021

1

Effect of advanced glycation end products on nocturia or sleep disorders: A longitudinal study.

Konishi S, Hatakeyama S, Imai A, Okita K, Kido K, Ozaki Y, Uemura N, Iwane T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 5;3(2):162-168. doi: 10.1002/bco2.114. eCollection 2022 Mar.

PMID: 35474730 .

2

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.

Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Okuyama Y, Kojima Y, Noro D, Tokui N, Okamoto T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):146-153. doi: 10.1002/bco2.117. eCollection 2022 Mar.

PMID: 35474729 .

3

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.

Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):154-161. doi: 10.1002/bco2.118. eCollection 2022 Mar.

PMID: 35474728 .

4

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

BJUI Compass (Report missing IFs). 2021 Oct 8;3(2):139-145. doi: 10.1002/bco2.119. eCollection 2022 Mar.

PMID: 35474727 .

5

Editorial Comment to A case of miliary tuberculosis following transurethral surgery and prostate biopsy after intravesical bacillus Calmette-Guerin immunotherapy.

Hatakeyama S, Ohyama C.

IJU Case Rep (Report missing IFs). 2021 Nov 11;5(1):47-48. doi: 10.1002/iju5.12387. eCollection 2022 Jan. PMID: 35005472 . No abstract available.

6

Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.

Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2022 Feb;40(2):64.e1-64.e8. doi: 10.1016/j.urolonc.2021.11.005. Epub 2021 Dec 30.

PMID: 34973857

7

Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.

Ozaki K, Hatakeyama S, Hamaya T, Okita K, Hashimoto Y, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2022 Apr;29(4):362-364. doi: 10.1111/iju.14778. Epub 2021 Dec 29.

PMID: 34965612 No abstract available.

8

Efficacy of one-surgeon basketing technique for stone extraction during flexible ureteroscopy for urolithiasis.

Anan G, Hattori K, Hatakeyama S, Ohyama C, Sato M.

Arab J Urol (IF: 2.1; Q2). 2021 Feb 20;19(4):447-453. doi: 10.1080/2090598X.2021.1889943. eCollection 2021.

PMID: 34881060 .

9

Simultaneous analysis of serum α 2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.

Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, Yoshimura K, Miyoshi E, Uemura H, Ohyama C, Nonomura N, Fujita K.

Br J Cancer (IF: 7.64; Q1). 2022 Mar;126(5):764-770. doi: 10.1038/s41416-021-01637-x. Epub 2021 Nov 20.

PMID: 34802050

10

Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries.

Konishi S, Narita T, Hatakeyama S, Yoneyama T, Yoneyama MS, Tobisawa Y, Noro D, Sato T, Togashi K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Sci Rep (IF: 4.38; Q1). 2021 Nov 11;11(1):22103. doi: 10.1038/s41598-021-01430-z.
PMID: 34764347 .

11

The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.

Okuyama Y, Okamoto T, Sasaki D, Ozaki K, Songee J, Hatakeyama S, Mikami T, Ohyama C.
Int Urol Nephrol (IF: 2.37; Q3). 2022 Jan;54(1):9-16. doi: 10.1007/s11255-021-03044-w. Epub 2021 Oct 29.
PMID: 34714460

12

The cell surface hyaluronidase TMEM2 is essential for systemic hyaluronan catabolism and turnover.

Tobisawa Y, Fujita N, Yamamoto H, Ohyama C, Irie F, Yamaguchi Y.
J Biol Chem (IF: 5.16; Q2). 2021 Nov;297(5):101281. doi: 10.1016/j.jbc.2021.101281. Epub 2021 Oct 6.
PMID: 34624311 .

13

Butyrylcholinesterase level as an independent prognostic factor for overall survival in patients on maintenance hemodialysis: a single-center retrospective study.

Fukushi K, Okamoto T, Ozaki Y, Ozaki K, Sasaki D, Miura Y, Okuyama Y, Tanaka Y, Imanishi K, Hatakeyama S, Saitoh F, Ohyama C.
Clin Exp Nephrol (IF: 2.8; Q3). 2022 Feb;26(2):190-197. doi: 10.1007/s10157-021-02140-6. Epub 2021 Sep 28.
PMID: 34581897

14

Characteristics of α 2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.

Yoneyama T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, Hatakeyama S, Narita T, Kodama H, Momota M, Ito H, Narita S, Tsushima F, Mitsuzuka K, Yoneyama T, Hashimoto Y, Duivenvoorden W, Pinthus JH, Kakeda S, Ito A, Tsuchiya N, Habuchi T, Ohyama C.
Prostate (IF: 4.1; Q2). 2021 Dec;81(16):1411-1427. doi: 10.1002/pros.24239. Epub 2021 Sep 21.
PMID: 34549452 .

15

External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.

Okita K, Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Dec;39(12):836.e11-836.e17. doi: 10.1016/j.urolonc.2021.08.015. Epub 2021 Sep 17.

PMID: 34544649

16

Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer.

Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.

Clin Cancer Res (IF: 12.53; Q1). 2021 Nov 15;27(22):6164-6173. doi: 10.1158/1078-0432.CCR-21-2328. Epub 2021 Sep 15.

PMID: 34526361

17

Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.

Numakura K, Muto Y, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T.

Cancer Med (IF: 4.45; Q2). 2021 Sep;10(17):5839-5846. doi: 10.1002/cam4.4130. Epub 2021 Jul 27.

PMID: 34313025

18

Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.

Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N.

Int J Clin Oncol (IF: 3.4; Q3). 2021 Oct;26(10):1947-1954. doi: 10.1007/s10147-021-01979-9. Epub 2021 Jun 30.

PMID: 34191191

19

Association between female urinary urgency and aponeurotic ptosis: Results from a community-based cross-sectional study in Japan.

Ozaki Y, Okamoto T, Miura Y, Iida K, Uemura N, Sugimura Y, Hatakeyama S, Urushidate S, Ohyama C. *Neurourol Urodyn* (IF: 2.7; Q3). 2021 Aug;40(6):1678-1685. doi: 10.1002/nau.24736. Epub 2021 Jun 26. PMID: 34174106

20

Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion.

Teoh JY, Chan EO, Kang SH, Patel MI, Muto S, Yang CK, Hatakeyama S, Chow TS, Mok A, Zhang R, Kijvikai K, Lee LS, Chen H, Ohyama C, Horie S, Chan ES.

Ann Surg Oncol (IF: 5.34; Q2). 2021 Dec;28(13):9209-9215. doi: 10.1245/s10434-021-10295-5. Epub 2021 Jun 21.

PMID: 34152523

21

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.

Okamoto T, Noro D, Hatakeyama S, Narita S, Mitsuzuka K, Sakurai T, Kawamura S, Hoshi S, Shimoda J, Tanaka T, Kawaguchi T, Ishidoya S, Ito A, Tsuchiya N, Habuchi T, Ohyama C.

BMC Cancer (IF: 3.15; Q2). 2021 May 25;21(1):605. doi: 10.1186/s12885-021-08206-8.

PMID: 34034691

22

Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.

Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, Narita S, Tanaka T, Noro D, Tokui N, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2021 Sep;28(9):899-905. doi: 10.1111/iju.14601. Epub 2021 May 24.

PMID: 34028105

23

Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.

Hatakeyama S, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2021 Aug;28(8):820. doi: 10.1111/iju.14593. Epub 2021 May 19.

PMID: 34013581 No abstract available.

24

Narrative review of urinary glycan biomarkers in prostate cancer.

Hatakeyama S, Yoneyama T, Tobisawa Y, Yamamoto H, Ohyama C.

Transl Androl Urol (IF: 2.44; Q2). 2021 Apr;10(4):1850-1864. doi: 10.21037/tau-20-964.

PMID: 33968674 . Review.

25

The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.

Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Dec;39(12):832.e17-832.e23. doi: 10.1016/j.urolonc.2021.03.011. Epub 2021 Apr 14.

PMID: 33865689

26

Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).

Iwamura H, Hatakeyama S, Momota M, Kojima Y, Narita T, Okamoto T, Fujita N, Hamano I, Togashi K, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Transl Androl Urol (IF: 2.44; Q2). 2021 Mar;10(3):1143-1151. doi: 10.21037/tau-20-1351.

PMID: 33850749 .

27

Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.

Muto Y, Narita S, Hatakeyama S, Maita S, Chiba S, Kubo K, Aoyama Y, Ito R, Takahashi Y, Takahashi S, Nakamura K, Honma N, Sato H, Koizumi A, Igarashi R, Okane K, Ishida T, Horikawa Y, Kumazawa T, Akihama S, Shimoda J, Suzuki T, Ohyama C, Habuchi T.

Med Oncol (IF: 3.06; Q3). 2021 Mar 13;38(4):37. doi: 10.1007/s12032-021-01480-3.

PMID: 33713196

28

Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.

Kubota Y, Hatakeyama S, Yoneyama T, Yoneyama MS, Hamano I, Konishi S, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

World J Urol (IF: 4.23; Q1). 2021 Sep;39(9):3265-3271. doi: 10.1007/s00345-021-03649-x. Epub 2021 Mar 6.

PMID: 33675416

29

Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.

Hatakeyama S, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2021 May;28(5):591-592. doi: 10.1111/iju.14539. Epub 2021 Mar 4.

PMID: 33663016 No abstract available.

30

The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites.

Irie F, Tobisawa Y, Murao A, Yamamoto H, Ohyama C, Yamaguchi Y.

J Biol Chem (IF: 5.16; Q2). 2021 Jan-Jun;296:100481. doi: 10.1016/j.jbc.2021.100481. Epub 2021 Feb 26.

PMID: 33647313 .

31

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis.

Narita T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Shimoda J, Kawaguchi T, Ishidoya S, Mitsuzuka K, Arai Y, Ito A, Tsuchiya N, Habuchi T, Ohyama C.

Transl Androl Urol (IF: 2.44; Q2). 2021 Jan;10(1):417-425. doi: 10.21037/tau-20-966.

PMID: 33532329 .

32

Editorial Comment from Dr Hatakeyama and Dr Ohyama to Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma.

Hatakeyama S, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2021 Apr;28(4):456-457. doi: 10.1111/iju.14508. Epub 2021 Feb 1.

PMID: 33525053 No abstract available.

33

Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.

Yoneyama T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, Uemura T, Ishizu T, Suzuki M, Hachinohe S, Ishiyama S, Nonaka M, Fukuda MN, Ohyama C.

BMC Cancer (IF: 3.15; Q2). 2021 Jan 29;21(1):105. doi: 10.1186/s12885-021-07815-7.
PMID: 33514332 . No abstract available.

34

Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.

Hamaya T, Hatakeyama S, Tanaka T, Kubota Y, Togashi K, Hosogoe S, Fujita N, Kusaka A, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C.

BJU Int (IF: 5.59; Q1). 2021 Oct;128(4):468-476. doi: 10.1111/bju.15346. Epub 2021 Feb 15.

PMID: 33484231 .

35

N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.

Kodama H, Yoneyama T, Tanaka T, Noro D, Tobisawa Y, Yamamoto H, Suto S, Hatakeyama S, Mori K, Yoneyama T, Hashimoto Y, Kakizaki I, Nakaji S, Ohyama C.

Cancer Med (IF: 4.45; Q2). 2021 Feb;10(4):1297-1313. doi: 10.1002/cam4.3727. Epub 2021 Jan 16.

PMID: 33455069 .

36

Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.

Yoneyama T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, Uemura T, Ishizu T, Suzuki M, Hachinohe S, Ishiyama S, Nonaka M, Fukuda MN, Ohyama C.

BMC Cancer (IF: 3.15; Q2). 2021 Jan 15;21(1):72. doi: 10.1186/s12885-020-07760-x.

PMID: 33446132 .

37

Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥ 75 years.

Togashi K, Hatakeyama S, Okamoto T, Kojima Y, Iwamura H, Fujita N, Narita T, Hamano I, Hamaya T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Oct;39(10):729.e17-729.e25. doi: 10.1016/j.urolonc.2020.12.001. Epub 2021 Jan 19.

PMID: 33353866

38

Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.

Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Tsushima E, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C.
Int J Urol (IF: 3.37; Q2). 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12.
PMID: 33314387

39

Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.

Horiguchi H, Hatakeyama S, Yoneyama T, Yoneyama MS, Tanaka T, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Yoshizawa T, Hashimoto Y, Kawaguchi T, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Apr;39(4):238.e9-238.e17. doi: 10.1016/j.urolonc.2020.11.029. Epub 2020 Dec 8.

PMID: 33308976

40

Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.

Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Takenaka A, Fujimoto K, Yamaguchi R, Habuchi T, Hashine K, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG).

Int J Urol (IF: 3.37; Q2). 2021 Feb;28(2):208-214. doi: 10.1111/iju.14435. Epub 2020 Nov 29.

PMID: 33283389

41

A Longitudinal Study of Bidirectional Relationships between Sleep Disorder and Frequency of Nocturia: Results from the Iwaki Health Promotion Project.

Konishi S, Hatakeyama S, Imai A, Kumagai M, Okamoto T, Okita K, Hamano I, Narita T, Kojima Y, Iwamura H, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Int (IF: 2.09; Q3). 2021;105(3-4):232-239. doi: 10.1159/000509976. Epub 2020 Dec 3.

PMID: 33271539

42

Editorial Comment.

Hatakeyama S, Hamano I, Ohyama C.

J Urol (IF: 7.45; Q1). 2021 Jan;205(1):107. doi: 10.1097/JU.0000000000001325.01. Epub 2020 Oct 23.

PMID: 33095100 No abstract available.

43

Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study). Hamaya T, Hatakeyama S, Momota M, Narita T, Iwamura H, Kojima Y, Hamano I, Fujita N, Okamoto T, Togashi K, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Int J Clin Oncol (IF: 3.4; Q3). 2021 Jan;26(1):199-206. doi: 10.1007/s10147-020-01798-4. Epub 2020 Oct 16.

PMID: 33079283

44

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

Kido K, Hatakeyama S, Numakura K, Tanaka T, Oikawa M, Noro D, Hosogoe S, Narita S, Inoue T, Yoneyama T, Ito H, Nishimura S, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C.

Int J Clin Oncol (IF: 3.4; Q3). 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16.

PMID: 33067647

45

Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study.

Iwamura H, Hatakeyama S, Narita S, Arai Y, Habuchi T, Ohyama C.

Int J Urol (IF: 3.37; Q2). 2021 Jan;28(1):125-127. doi: 10.1111/iju.14392. Epub 2020 Oct 8.

PMID: 33034051 No abstract available.

46

Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer.

Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Mar;39(3):194.e9-194.e16. doi: 10.1016/j.urolonc.2020.08.026. Epub 2020 Sep 15.

PMID: 32943344

47

The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study).

Togashi K, Hatakeyama S, Kojima Y, Momota M, Narita T, Iwamura H, Hamano I, Hamaya T, Fujita N, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Mar;39(3):192.e7-192.e14. doi: 10.1016/j.urolonc.2020.08.010. Epub 2020

Aug 26.

PMID: 32861619

48

Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.

Fujita N, Hatakeyama S, Okita K, Momota M, Narita T, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Mar;39(3):191.e9-191.e16. doi: 10.1016/j.urolonc.2020.06.032. Epub 2020 Jul 23.

PMID: 32713622

49

Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study).

Kodama H, Hatakeyama S, Momota M, Togashi K, Hamaya T, Hamano I, Fujita N, Kojima Y, Okamoto T, Yoneyama T, Yamamoto H, Yoshikawa K, Yoneyama T, Hashimoto Y, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Mar;39(3):191.e1-191.e8. doi: 10.1016/j.urolonc.2020.06.019. Epub 2020 Jul 17.

PMID: 32684512

50

Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer.

Fujita N, Hatakeyama S, Okita K, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.

Urol Oncol (IF: 3.5; Q3). 2021 Jan;39(1):75.e9-75.e16. doi: 10.1016/j.urolonc.2020.06.011. Epub 2020 Jul 12.

PMID: 32665123

51

Overactive bladder and sleep disturbance have a significant effect on indoor falls: Results from the community health survey in Japan.

Konishi S, Hatakeyama S, Imai A, Kumagai M, Okita K, Togashi K, Hamaya T, Hamano I, Okamoto T, Iwamura H, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.

Low Urin Tract Symptoms (IF: 1.59; Q4). 2021 Jan;13(1):56-63. doi: 10.1111/luts.12326. Epub 2020 Jun 4.

PMID: 32496639

52

Altered gut microbiome associated with overactive bladder and daily urinary urgency.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol (IF: 4.23; Q1). 2021 Mar;39(3):847-853. doi: 10.1007/s00345-020-03243-7. Epub 2020 May 17.

PMID: 32419054

53

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol (IF: 4.23; Q1). 2021 Jan;39(1):169-175. doi: 10.1007/s00345-020-03167-2. Epub 2020 Mar 19.

PMID: 32193653